AMGEN INC (AMGN) |
Consensus Forecast of AMGEN INC Revenue in Millions  |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
11/07 |
| $14,771.00 |
$15,003.00 |
$14,642.00 |
$15,104.04 |
$15,724.51 |
1.6% |
|
| Consensus Forecast of AMGEN INC EPS |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| $3.20 |
$3.75 |
$4.20 |
$4.48 |
$4.89 |
$5.03 |
$5.38 |
$5.97 |
|
| Discussion | | Amgen expects 2010 adjusted EPS to be in the range of $5.05 to $5.25, excluding stock option expense, certain expenses related to prior acquisitions, and the non-cash interest expense resulting from a change in accounting for its convertible debt. Management expects EPS growth to be driven by strong expense control and share buybacks.
| Last edited Mon Feb 08, 2010 05:03 AM
by SudiptaMukherjee (Zacks Investment Research) |  |
EPS FORECASTS
|
This section is designed to find errors as the consensus forecast of EPS. The consensus forecasts for the lines in the AMGEN INC Income Statement are shown and below each consensus forecast is a wiki section to discuss why the consensus forecast of that item may be high or low
|
|
| Consensus Forecasts of Total Revenue |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
12/05 |
| 1. Total Revenue |
$12,430.0 |
$14,268.0 |
$14,771.1 |
$15,001.7 |
$14,642.1 |
$15,115.6 |
$15,747.6 |
$16,716.0 |
4.3% |
|
| Discussion by Wiki Users | | The company expects FY10 total revenue to be in the guidance range of $15.1 billion-$15.5 billion which assumes both an EU and US launch of Prolia.
| Last edited Mon Feb 08, 2010 05:03 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Fully Diluted Shares Outstanding |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| Fully Diluted Shares Outstanding |
1258.0 |
1186.0 |
1121.3 |
1074.2 |
1021.3 |
982.6 |
962.8 |
945.0 |
|
| Consensus Forecasts of Cost of Goods Sold |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 2. Cost of Goods Sold |
$2,035.0 |
$2,081.8 |
$2,295.4 |
$2,203.0 |
$2,079.8 |
$2,151.9 |
$2,256.3 |
$2,380.0 |
| Percent of Revenue |
16% |
15% |
16% |
15% |
14% |
14% |
14% |
14% |
| 3. Gross Profit (1-2) |
$10,395.00 |
$12,186.20 |
$12,475.70 |
$12,798.70 |
$12,562.30 |
$12,963.70 |
$13,491.30 |
$14,336.00 |
| Percent of Revenue |
84% |
85% |
84% |
85% |
86% |
86% |
86% |
86% |
|
| Consensus Forecasts of Selling, General and Administrative Expense |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 4. Selling, General and Administrative Expense |
$2,792.0 |
$3,240.3 |
$3,378.5 |
$3,715.7 |
$3,748.9 |
$3,920.1 |
$4,066.5 |
$4,278.1 |
| Percent of Revenue |
22% |
23% |
23% |
25% |
26% |
26% |
26% |
26% |
|
| Discussion by Wiki Users | | R&D and SG&A expenses would increase if Prolia is launched.
| Last edited Mon Feb 08, 2010 05:04 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Research and Development |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 5. Research and Development |
$2,302.0 |
$3,200.7 |
$3,097.7 |
$2,927.1 |
$2,756.9 |
$2,793.4 |
$2,882.0 |
$3,009.6 |
| Percent of Revenue |
19% |
22% |
21% |
20% |
19% |
18% |
18% |
18% |
|
| Consensus Forecasts of Pre - Tax Income |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 7. Pre - Tax Income |
$5,321.0 |
$5,930.2 |
$6,013.0 |
$6,220.0 |
$6,036.3 |
$6,316.2 |
$6,626.0 |
$7,131.9 |
| 8. Tax provisions |
$1,298.0 |
$1,313.8 |
$1,296.2 |
$1,351.9 |
$1,022.0 |
$1,272.6 |
$1,387.2 |
$1,513.4 |
| Percent of Revenue |
24% |
22% |
22% |
22% |
17% |
20% |
21% |
21% |
| 9. Net Income (7-8) |
$4,023.00 |
$4,616.40 |
$4,716.80 |
$4,868.10 |
$5,014.30 |
$5,043.60 |
$5,238.80 |
$5,618.50 |
|
| Discussion by Wiki Users | | The tax rate is expected to be 20-21% in 2010.
| Last edited Mon Feb 08, 2010 05:04 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| AMGN (AMGEN INC) |
$14,926.00 |
$4,753.00 |
23.0% |
8% |
10.29 |
3.3 |
8.5 |
Industry Mean |
|
|
-53% |
16% |
14.37 |
408.7 |
12.7 |
| S&P 500 |
|
|
23% |
11% |
13.71
| 1.9 |
|
|
|
|
|
|
|
|
|
GENZ (GENZYME-GENERAL) |
$4,441.00 |
$116.53 |
5.0% |
16% |
24.45 |
2.9 |
13.8 |
BIIB (BIOGEN IDEC INC) |
$4,450.00 |
$943.59 |
18.4% |
9% |
10.69 |
2.8 |
8.6 |
GILD (GILEAD SCIENCES) |
$7,567.00 |
$2,901.54 |
48.1% |
15% |
10.39 |
4.2 |
10.9 |
CF is operating cash flow plus after-tax interest expense. |
|
| Discussion of Relative Valuation | | No comments yet. Be the first | | |
|
|
| | |
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 06:15:34 CDT by WikiMigrationBot.
|
